Rajendra S*, Sharma P. Causal Link of Human Papillomavirus in Barrett Esophagus and Adenocarcinoma: Are We There Yet? Cancers 2023;15(3):873. doi: 10.3390/cancers15030873. [IF=6.57].
Link
Rajendra S * . Diagnosis and Management of Barrett’s Esophagus: An updated ACG Guideline. Am J Gastroenterol 2022; 117:1880. (Correspondence). [IF= 12.04].
Link
Sundaram S, Olson S, Sharma P, Rajendra S. A Review of the Impact of the COVID-19 Pandemic on Colorectal Cancer Screening: Implications and Solutions. Pathogens. 2021 Nov 19;10(11):1508. doi: 10.3390/pathogens10111508. [IF=4.57].
Link
Rajendra S * , Pavey D, McKay O, Merrett N, Gautam SD. Human papillomavirus infection in esophageal squamous cell carcinoma and esophageal adenocarcinoma: a concise review. Ann N Y Acad Sci. 2020 Dec;1482(1):36-48. [IF 6.49, 5 Year IF= 6.57].
Link
Rajendra S * , Sharma P, Gautam S, Saxena M, Kapur, Sharma P, Merrett N, Yang T, Santos, LD, Pavey D, Sharaiha O, McKay O, Dixson H, Xuan W. Association of biomarkers for human papillomavirus with survival among adults with Barrett high-grade dysplasia and esophageal adenocarcinoma. JAMA Netw Open. 2020; 3(2):e1921189. doi: 10.1001/jamanetworkopen.2019.21189. [IF=13.35]. A world first paper documenting human papillomavirus related biomarkers and association with improved survival in Barrett’s high-grade dysplasia and oesophageal adenocarcinoma.
Link
Rajendra S * , Xuan W, Hufnagel K, Sharma P, Pavey D, Alhajjiri N, Rattan A, Wang B. Antibodies against human papillomavirus proteins in Barrett’s dysplasia and intramucosal esophageal adenocarcinoma. Ann N Y Acad Sci. 2020: 1470: 44-56. [IF 6.49, 5 Year IF= 6.57].
Link
Parameshwaran K, Sharma P, Rajendra S*, Stelzer-Braid S, Xuan W, Rawlinson WD. Circulating human papillomavirus DNA detection in Barrett’s dysplasia and esophageal adenocarcinoma. Dis Esophagus 2019 Jul 17. pii: doz064. doi: 10.1093/dote/doz064. [IF 3.43].
Link
Rajendra S*, Xuan W, Merrett N, Sharma P, Sharma P, Pavey D, Yang T, Santos LD, Sharaiha O, Pande G, Cosman P, Wu X, Wang B. Survival rates for patients with Barrett high-grade dysplasia and esophageal adenocarcinoma with or without human papillomavirus infection. JAMA Netw Open 2018 Aug 3; 1 (4): e181054. Doi: 10.1001/jamanetworkopen. 2018. 1054. [IF=13.35].
Accompanied by Editorial. A world first paper documenting improved survival in human papillomavirus associated oesophageal adenocarcinoma versus virus negative oesophageal cancer.
Link
Rajendra S * , Yang T, Xuan W, Sharma P, Davey P, Soon Lee C, Le S, Collins J, Wang B. Active human papillomavirus involvement in Barrett’s dysplasia and oesophageal adenocarcinoma is characterized
by wild-type p53 and aberrations of the retinoblastoma protein pathway. Int J Cancer 2017; 141: 2037-2049. Jul 19. Doi: 10.1002/ijc.30896 [IF=7.31]
Link
Rajendra S,* Wang B,* Merrett N, Sharma P, Humphris J, Lee HC, Wu J.* Genomic analysis of HPV positive versus HPV negative oesophageal adenocarcinoma identifies a differential mutational landscape. J Med Genet 2016; 53: 227-231 Published Online First: 15 October 2015 doi:10.1136/jmedgenet-2015-103411 [IF 6.33]
[First paper in the world to demonstrate distinct genomic differences between these 2 types of esophageal cancers indicating differing biological mechanisms of tumour formation]
Link
Rajendra S*. Barrett’s oesophagus: Can meaningful screening and surveillance guidelines be formulated based on new data and rejigging the old paradigm? Best Pract Res Clin Gastroenterol 2015; 29: 69-79. IF 3.632
[Invited Review by Professor Ernst Kuipers, Editor of Journal and Associate Editor, Gut]
Link
Whiteman DC*, Appleyard M, Bahin FF, Bobryshev YV, Bourke MJ, Brown I, Chung A, Clouston A, Dickins E, Emery J, Eslick GD, Gordon LG, Grimpen F, Hebbard G, Holliday L, Hourigan L, Kendall BJ, Lee EY, Levert A, Lord RV, Lord SJ, Maule D, Moss A, Norton I, Olver I, Pavey D, Raftopoulos S, Rajendra S, Schoeman M, Singh R, Sitas F, Smithers BM, Taylor A, Thomas ML, Thomson I, To H, von Dincklage J, Vuletich C, Watson DI, Yusoff IF. Australian clinical practice guidelines for the diagnosis and management of Barrett’s Esophagus and Early Esophageal Adenocarcinoma. J Gastroenterol Hepatol. 2015; 30: 804-20. [IF= 4.36].
Link
Rajendra S*, Wang B, Pavey D, Sharma P, Yang T, Lee CS, Gupta N, Ball MJ, Gill RS, Wu X. Persistence of Human Papillomavirus, Overexpression of p53, and Outcomes of Patients After Endoscopic Ablation of Barrett’s Esophagus. Clin Gastroenterol Hepatol. 2015;13: 1364-1368. 2014 Nov 21. pii: S1542-3565(14)01708-X. doi: 10.1016/j.cgh.2014.11.017. [IF= 11.38] [Subject of an Editorial and Editor’s Choice]
Link
Wang B, Rajendra S * , Pavey D, et al. Viral load and integration status of high-risk HPV in the Barrett’s metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2013; 108: 1814-1816. [IF 12.04]
[First paper in the world to demonstrate that viral integration is an early event and that viral load and integration status increases with disease severity along the sequence. First pictures in the world showing HPV located within the columnar, dysplastic and oesophageal cancer cells and NOT squamous epithelium!]
Link
Rajendra S*, Wang B, Snow ET, et al. Transcriptionally active human papillomavirus is strongly associated with Barrett’s dysplasia and esophageal adenocarcinoma. Am J Gastroenterol 2013;108:1082–1093. [Editor’s Choice]. [IF 12.04]
[First study in the world to detect biologically active high risk HPV in the Barrett’s dysplastic/non-dysplastic tissue and adenocarcinoma]
Link
Rajendra S * , Sharma P*. Management of Barrett’s oesophagus and intramucosal oesophageal cancer: a review of recent development. Therapeutic Advances in Gastroenterology 2012; 5 (5): 285-299. [IF 4.80]
[Invited review article from world experts in their field of specialization in gastroenterology]
Link
Rajendra S, Sharma P*. Barrett’s oesophagus and cancer risk: a more realistic estimate. Semin Thorac Cardiovasc Surg 2011; 23(4):261-2.
[Invited Editorial: American Society of Cardiothoracic Surgeons]
Link
Rajendra S*. Barrett’s oesophagus in Asians – Are ethnic differences due to genes or the environment? J Int Med 2011; 270 (5): 421-7. [IF 13.06]
[Invited Review article from the Editor, Journal of Internal Medicine, Karolinska Institute, Sweden] [Subject of an Editorial].
Link
Rajendra S*, Robertson IK. Similar immunogenetics of Barrett’s oesophagus and cervical neoplasia: Is HPV the common denominator? J Clin Pathol 2010; 63: 1-3. [IF 4.46]
[Full paper describing similar immunogenetics of cervical neoplasia and Barrett’s metaplasia/dysplasia. A world first.]
Link
Rajendra S*, Ackroyd R, Robertson IK et al. Helicobacter pylori, ethnicity and the gastro-oesophageal reflux disease spectrum: a study from the East. Helicobacter 2007; 12 (2): 177-83. [IF 5.18]
[This paper demonstrated for the first time that in the presence of H. pylori infection, patients had a 50% reduction in the length of Barrett’s oesophagus]
Link
Rajendra S, Ackroyd R, Murad S et al. Barrett’s oesophagus and HLA-B0702 / HLA-B*0706. Aliment Pharmacol Ther 2006; 23:1375-6. [IF: 9.52]
[This research letter reports on the subtyping of the HLA-B7 gene associated with Barrett’s oesophagus which we reported on earlier; again a world first]
Link
Rajendra S*. Immunomodulatory effects of non-steroidal anti-inflammatory drugs in Barrett’s oesophagus. Lancet Oncology 2006; 7: 103-4. [IF 54.43]
[I reported for the very first time another mechanism of action of non-steroidal anti-inflammatory drugs and cancer chemoprevention]
Link
Rajendra S*, Ackroyd R, Karim N et al. Loss of HLA class I and gain of class II expression are early events in carcinogenesis – clues from a study of Barrett’s oesophagus. J Clin Pathol 2006; 59: 952-57. [IF 4.46].
[We showed for the very first time that immunogenetic changes occur at the earliest stage of the metaplasia-carcinoma sequence of Barrett’s oesophagus i.e. at the pre-malignant stage. Furthermore, we
demonstrated that non-steroidal anti-inflammatory drugs protected against these immunogenetic changes thus affording cancer chemoprevention in Barrett’s oesophagus]
Link
Rajendra S*, Ho JJ. Colonic diverticular disease in a multiracial Asian population has an ethnic predilection. Eur J Gastroenterol Hepatol 2005; 17 (8): 871-875. [IF 2.58].
Link
Rajendra S*, Ackroyd R, Mohan C. South Asian origin as a risk factor for GERD. Aliment Pharmacol Ther 2005; 22: 75-76. [IF 9.52]
[We explain for the very first time the reasons for ethnic differences in Barrett’s oesophagus based on genetic markers and migration patterns]
Link
Rajendra S*, Ackroyd R, Murad S et al. HLA determinants of susceptibility to Barrett’s oesophagus in Asians: a preliminary study. Aliment Pharmacol Ther 2005; 21: 1377-1383. [IF 9.52]
[A world’s first. First study to identify a genetic association with Barrett’s oesophagus]
Link
Rajendra S*, Ho JJ, Arokiasamy J. Risk of colorectal adenomas in a multiethnic Asian patient population: race does not matter. J. Gastroenterol. Hepatol. 2005; 20 (1): 51-55. [IF=3.483].
Ethnic disparity in the prevalence of partial villous atrophy and post- infective tropical malabsorption J. Gastroenterol. Hepatol. 2004; 19 (4): 472-474. [IF= 4.36]
[First paper on ethnic differences in tropical sprue. A new, simplified practical way of diagnosing tropical sprue was described]
Link
Rajendra S*, Kutty K, Karim N. Ethnic differences in the prevalence of endoscopic oesophagitis and Barrett’s oesophagus: the long and short of it all. Dig Dis Sci 2004; 49 (2): 237-242. [IF= 3.48]
[A often cited landmark paper on the epidemiology of Barrett’s oesophagus in a multi-ethnic population. Data quoted in chapters of standard texts on Barrett’s oesophagus and cited in the latest Asia-Pacific guidelines on the management of Barrett’s oesophagus]
Link
Rajendra S*, Alahuddin S. Racial differences in the prevalence of heartburn in an ethnically mixed non-migrant population. Aliment Pharmacol Ther 2004; 19 (3): 375-376 [IF= 9.52].
Link